```
554 Supplementary Materials
```

555 Additional file 1 — Stan code for the Bayesian multivariate hierarchical model

```
556 1 data {
      int<lower=0> N;
                                       // number of observations
557 2
      int<lower=0> D;
                                       // number of of binary outcomes
558 3
                                       // number of WHO categories
559 4
      int<lower=2> L:
      int <lower=0> P_main;
                                       // number of pre-treatment
560.5
        characteristics in the main effects term
561
      int<lower=0> P_inter;
                                       // number of pre-treatment
562 6
563
        characteristics in the interaction effects term
      int<lower=1,upper=L> y_ord[N]; // vector of ordinal outcomes
564 7
      int<lower=0,upper=1> y_b[N,D]; // matrix of D binary outcomes (N x D
565 8
         matrix)
566
      int<lower=0,upper=1> A[N];
                                       // treatment or control
567 9
      row_vector[P_main] x_main[N]; // pre-treatment characteristics in
568 0
       the main effects term (N x P_main matrix)
569
      row_vector[P_inter] x_inter[N];// pre-treatment characteristics in
570 1
        the interaction effects term (N x P_inter matrix)
571
572 2 }
573L3
574.4 parameters {
                                       // cut-points for cumulative odds
575L5
      ordered[L-1] tau;
        model
576
      vector<lower=0>[(P_inter + 1)] sigma_beta; // sd of outcome-specific
5776
         treatment main effect and interaction effect
578
      vector[D] beta_0;
                                       // outcome-specific intercepts for D
579.7
       binary outcomes
580
      matrix[P_main,(D + 1)] beta_1; // covariates main effect for D
5811.8
        binary outcomes and 1 ordinal outcome (P_main x (D + 1) matrix)
582
      vector[(P_inter + 1)] beta_star; // pooled treatment main effect and
583.9
         pooled interaction effect across all outcomes
584
5852.0
      // non-central parameterization
58621
58722
5882.3
      matrix[(P_inter + 1),(D + 1)] z_beta_int;
58924 }
59025
59126 transformed parameters {
      matrix[(P_inter + 1),(D + 1)] beta_int; // outcome-specific
59227
        treatment main effect and interaction effect ((P_{inter} + 1) x (D +
593
         1) matrix)
594
59528
      vector[D] yhat_b[N];
      real yhat_ord[N];
59629
59730
      for (j in 1:(P_inter + 1))
5981
         for (k in 1:(D + 1)){
59982
           beta_int[j,k] = beta_star[j] + sigma_beta[j] * z_beta_int[j,k];
60033
     }
60134
60235
     for (i in 1:N){
60386
```

```
for (k in 1:D){
60437
           yhat_b[i,k] = beta_0[k] + x_main[i] * beta_1[,k] + (
60588
        append_col(1, x_inter[i]) * beta_int[,k]) * A[i];
606
        }
60739
        yhat_ord[i] = x_main[i] * beta_1[,D+1] + (append_col(1, x_inter[
60810
        i]) * beta_int[,D+1]) * A[i];
609
      }
61041
61142 }
61243
6134
6145 model {
61516
      // priors
61617
61748
      sigma_beta ~ exponential(1);
61819
      beta_star ~ normal(0,2.5);
61950
      to_vector(beta_1) ~ normal(0,2.5);
62051
      to_vector(z_beta_int) ~ std_normal();
62152
62253
62354
      for (1 in 1:(L-1)){
       tau[1] ~ student_t(3,0,8);
62455
      }
6256
6267
       for (k in 1:D){
62758
        beta_0[k] ~ student_t(3,0,8);
62859
      }
62950
63051
      // outcome model
63152
63253
      for (i in 1:N){
63354
        y_ord[i] ~ ordered_logistic(yhat_ord[I], tau);
63465
        for (k in 1:D){
63566
          y_b[i,k] ~ bernoulli_logit(yhat_b[i,k]);
63637
        }
63758
63859
      }
63970 }
```

- 640 Additional file 2 Main analysis: comparing the performance of the Bayesian multivariate and univariate models
- 641 when the true ITR is determined by potential outcomes
- <sup>642</sup> To implement this potential outcomes-based ITR, we first consider the patient characteristics  $\tilde{x}_i$  along with the true
- values of parameters from the data generation process. Next, we use the simstudy package [43] to generate
- potential primary ordinal outcomes for subjects receiving the control treatment  $(y_{A=0}^{(1)})$  and the experimental
- treatment  $(y_{A=1}^{(1)})$ . The optimal ITR is derived from the indicator function  $I(y_{A=1}^{(1)} < y_{A=0}^{(1)})$ , which evaluates
- 646 whether the experimental treatment outcome is better than the control treatment outcome.
- 647 Utilizing this new potential outcomes-based ITR, the subsequent plot (Figure A1) illustrates the comparison of PCD and AUC values between the Bayesian multivariate and univariate models across varying training set sizes. In



**Figure A1** Utilizing the new potential outcomes-based ITR: the boxplots of PCD and AUC in the test sets, comparing the multivariate (orange) and the univariate (blue) models across different training set sizes (as indicated in the x-axis).

648

comparison to Figure 1, the improvement in prediction using the multivariate model is less remarkable. This can be attributed to the fact that generating potential outcomes based on probability inherently involves more randomness.

<sup>651</sup> The gain in estimation is relatively small compared to the magnitude of this randomness. Consequently, when

considering prediction error, the improvement becomes less noticeable as it is overshadowed by the noise introduced

653 by the randomness.



654 Additional file 3 — Sensitivity analysis: comparing the performance of the Bayesian multivariate and univariate

655 models when the true ITR is determined by potential outcomes

656 Compared to Figure 2, the utilization of this new potential outcomes-based ITR yields less remarkable improvement

in the multivariate model's performance. This could be due to the probabilistic nature of generating potential

- outcomes, which inherently involves more randomness. Despite the gain in estimation, the magnitude of this
- randomness is relatively large, resulting in a small improvement that is overshadowed by the introduced noise when
- 660 considering prediction error.

Additional file 4 — The WHO 11-point COVID-19 clinical status scale. 661

- 0: Uninfected, no viral RNA detected
- 1: Asymptomatic, viral RNA detected
- 2: Symptomatic, independent

- Symptomatic, assistance needed 3:
- 4: Hospitalized, no oxygen therapy
- 5: Hospitalized, oxygen by mask or nasal prongs
- Hospitalized, oxygen by non-invasive ventilation or high flow 6:
- 7: Intubation & mechanical ventilation,  $pO_2/FiO_2 \ge 150$  (or  $SpO_2/FiO_2 \ge 200)^a$
- 8: Mechanical ventilation,  $pO_2/FiO_2 < 150$  (or SpO $_2/FiO_2 < 200$ ) or vasopressors
- 9: Mechanical ventilation,  $pO_2/FiO_2 < 150$  and vasopressors, dialysis, or ECMO<sup>b</sup>

Dead 10:

 ${}^{a}pO_{2}$ : partial pressure of oxygen, FiO<sub>2</sub>: fraction of inspired oxygen, SpO<sub>2</sub>: oxygen saturation. <sup>b</sup>ECMO: extracorporeal membrane oxygenation.

Table A1 The WHO 11-point COVID-19 scale definition[39].

	Control $(n = 1097)$	CCP (n = 1190)
WHO = 0	114	150
WHO=1	151	168
WHO = 2	365	386
WHO = 3	134	142
WHO = 4	45	45
WHO = 5	86	84
WHO = 6	29	52
WHO = 7	23	30
WHO = 8	23	36
WHO = 9	33	22
WHO=10	94	75

Table A2 The number of patients at different clinical stages of COVID-19 measured on the WHO 11-point scale at day 14 by treatment group.

- 662 Additional file 5 Goodness-of-fit using posterior predictive checking
- 663 In evaluating the suitability of a statistical model, it is crucial to determine whether the model provides an accurate
- representation of the observed data. This is particularly important for models like the *co* model, which is built upon
- a strong assumption of proportional cumulative odds. Posterior predictive checking serves as an effective way of
- assessing a model's goodness-of-fit [47, 48]. This method operates on the premise that a well-fitted model should
- enable the generation of replicated data  $(D^{rep})$  that resembles the observed data  $(D^{original})$  [49].
- 668 The lack of fit can be measured by the Bayesian p-value, which represents the probability of the test statistic (e.g.,
- $P(Y \le y), y = 0, \dots, 9)$  for  $D^{\mathsf{rep}}$  being equal to or exceeding the test statistic for  $D^{\mathsf{original}}$ . A Bayesian p-value
- approaching zero or one signifies a potential issue with the model's fit, whereas a value near 0.5 suggests that the
- 671 model captures the data well [42, 57]. We employed the procedure outlined in [41] to examine the *co* model's fit to 672 the observed data and to compute the Bayesian p-value.
- Table A3 provides the results of posterior predictive checking based on ten test statistics (along with their 95% Crls)
- 674 for both the multivariate model (6) and univariate model (7). Our analysis confirmed the satisfactory fit of both
- 675 models to the data.

Treatment	Control			CCP		
Test quantity: % subjects	$T(D^{\text{original}})$	95% int. for $T(D^{rep})$	Bayesian P value	$T(D^{original})$	95% int. for $T(D^{rep})$	Bayesian P value
Multivariate model						
WHO $\leq 0$	10.39	[8.39, 12.94]	0.55	12.61	[10.08, 14.71]	0.39
$WHO \leq 1$	24.16	[20.51, 26.80]	0.34	26.72	[23.28, 29.58]	0.41
WHO $\leq 2$	57.43	[52.42, 59.43]	0.19	59.16	[55.71, 62.52]	0.48
WHO $\leq$ 3	69.64	[65.36, 71.93]	0.29	71.09	[68.24, 74.45]	0.55
WHO $\leq$ 4	73.75	[69.92, 76.12]	0.32	74.87	[72.44, 78.32]	0.63
WHO $\leq 5$	81.59	[78.21, 83.68]	0.34	81.93	[80.17, 85.29]	0.74
$WHO \leq 6$	84.23	[82.22, 87.15]	0.64	86.30	[83.78, 88.40]	0.44
WHO $\leq$ 7	86.33	[84.78, 89.43]	0.74	88.82	[86.13, 90.50]	0.33
WHO $\leq 8$	88.42	[87.69, 91.89]	0.90	91.85	[88.82, 92.69]	0.14
WHO $\leq$ 9	91.43	[90.43, 94.07]	0.81	93.70	[91.26, 94.71]	0.22
Univariate model						
$WHO \leq 0$	10.39	[8.57, 13.13]	0.62	12.61	[9.83, 14.54]	0.32
$WHO \leq 1$	24.16	[20.78, 27.07]	0.41	26.72	[23.03, 29.41]	0.36
$WHO \leq 2$	57.43	[52.42, 59.80]	0.23	59.16	[55.55, 62.44]	0.46
WHO $\leq$ 3	69.64	[65.45, 72.20]	0.31	71.09	[68.15, 74.45]	0.55
$WHO \leq 4$	73.75	[69.83, 76.30]	0.34	74.87	[72.44, 78.40]	0.62
WHO $\leq$ 5	81.59	[78.12, 83.87]	0.35	81.93	[80.17, 85.29]	0.74
$WHO \leq 6$	84.23	[82.04, 87.24]	0.64	86.30	[83.78, 88.49]	0.45
WHO $\leq$ 7	86.33	[84.69, 89.52]	0.74	88.82	[86.13, 90.50]	0.34
WHO $\leq 8$	88.42	[87.60, 91.89]	0.89	91.85	[88.82, 92.69]	0.14
WHO $\leq$ 9	91.43	[90.34, 94.17]	0.81	93.70	[91.34, 94.79]	0.23

Table A3 Summary of posterior predictive checking based on the ten test statistics.